// App-Quantinova.ai

S173 : T-CELL ACTIVATION AND MYELOMA CELL KILLING CONFIRM THE MODE OF ACTION OF RG6234, A NOVEL GPRC5D T-CELL ENGAGING BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

Researchers

Presenter

  • Iryna Dekhtiarenko

Principal Investigators

  • Inga Clausen

  • Hans-Joachim Helms

  • Sara Belli

  • Tanja Fauti

  • Jan Eckmann

  • Pablo Umana

  • Wolfgang Jacob

  • Meike Schneider

  • Caroline Hasselbalch Riley

  • Martin Hutchings

  • Sung-Soo Yoon

  • Youngil Koh

  • Salomon Manier

  • Thierry Facon

  • Simon J Harrison

  • Jeremy Er

  • Francesco Volzone

  • Antonio Pinto

  • Enrique M Ocio

  • Ana Alfonso-Pierola

  • Paula Rodrguez Otero

  • Fritz Offner

  • Anna Guidetti

  • Paolo Corradini

  • Cyrille Hulin

  • Cyrille Touzeau

  • Philippe Moreau

  • Rakesh Popat

  • Rita Mazza

  • Carmelo Carlo-Stella

  • Ann-Marie E Brske

Medical Centers

  • Roche Pharma Research

  • Rigshospitalet, Copenhagen, Denmark

  • Seoul National University College of Medicine, Seoul, Korea

  • Rigshospitalet, Copenhagen, Denmark

  • Istituto Nazionale Tumori, Milano, Italy

  • University Hospital of Lille, Lille, France

  • CHU Bordeaux, Bordeaux, France

  • Hospital Universitario Marqués de Valdecilla. IDIVAL. Universidad de Cantabria., Cantabria, Spain

  • Clínica Universidad de Navarra, Navarra,Espanha

  • Clínica Universidad de Navarra, Navarra,Espanha

  • Istituto Nazionale Tumori, Fondazione 'G. Pascale', IRCCS,Napoli,Itália

  • CHU nantes,Nantes ,Francia

  • Universitair Ziekenhuis Gent, Ghent, Belgium

  • Clinica Universidad de Navarra,Madrid,Испания

  • CHU nantes,Nantes ,Francia

  • Clinica Universitaria de Navarra, Navarra, Spain

  • Roche Pharma Research and Early Development (pRED), Roche Innovation Center Penzberg, Penzberg, Germany

  • Roche Pharma Research and Early Development (pRED), Roche Innovation Center Basel, Basel, Switzerland

  • Seoul National University College of Medicine,Seoul,Corée, République De

  • Rigshospitalet, Copenhagen, Denmark

  • Department of Biomedical Sciences, Humanitas University and Department of Oncology and Hematology, IRCCS

  • Department of Biomedical Sciences, Humanitas University and Department of Oncology and Hematology, IRCCS Humanitas Research Hospital,Milano,Italie

  • Clinica Universidad de Navarra,

  • CHU de Bordeaux,Bordeaux,Франция

  • Roche Pharma Research and Early Development (pRED), Roche Innovation Center Penzberg, Penzberg, Germany

  • Clinica Universitaria de Navarra, Navarra, Spain

  • Lille University Hospital,Lille,França

  • Rigshospitalet, Copenhagen, Denmark

  • Istituto Nazionale Tumori, Milano, Italy

  • Roche Pharma Research and Early Development, Roche Innovation Center Munich, Munich, Germany

  • , Hospital Un

  • Roche Pharma Research and Early Development (pRED), Roche Innovation Center Basel, Basel, Switzerland

  • Istituto Nazionale Tumori, Fondazione 'G. Pascale', IRCCS,Napoli,Itália

  • Roche Pharma Research and Early Development (pRED), Roche Innovation Center Basel, Basel, Switzerland

  • Istituto Nazionale Tumori, Fondazione 'G. Pascale', IRCCS,Napoli,Itália

  • Hospital Universitario Marqués de Valdecilla. IDIVAL. Universidad de Cantabria., Cantabria, Spain

  • Roche Pharma Research and Early Development, Roche Innovation Center Munich, Munich, Germany

  • Clinica Universitaria de Navarra, Navarra, Spain

  • Istituto Nazionale Tumori, Milano, Italy

  • Universitair Ziekenhuis Gent, Ghent, Belgium

  • Clínica Universidad de Navarra, Navarra,Espanha

  • CHU nantes,Nantes ,Francia

  • Roche Pharma Research and Early Development, Roche Innovation Center Munich, Munich, Germany

  • Seoul National University College of Medicine, Seoul, Korea

  • Universitair Ziekenhuis Gent, Ghent, Belgium

  • Roche Pharmaceutical Research & Early Development,Roche Innovation Center Munich,Penzberg,Germany

  • Hospital Universitario Marqués de Valdecilla. IDIVAL. Universidad de Cantabria., Cantabria, Spain

  • Lille University Hospital,Lille,França

  • Istituto Nazionale dei Tumori,Milano,Италия

  • Roche Pharma Research and Early

  • Seoul National University College of Medicine, Seoul, Korea

  • Lille University Hospital,Lille,França

  • Istituto Nazionale Tumori, Milano, Italy

  • CHU nantes,Nantes ,Франция

  • University College London Hospitals NHS Trust, London, United Kingdom

  • Seoul National University College of Medicine, Seoul, Korea

  • Pathology,Peter MacCallum Cancer Centre,Melbourne,Australia;Sir Peter MacCallum Department of Oncology,The University of Melbourne,Parkville,Australia

  • Lille University Hospital,Lille,Франция

  • Istituto Nazionale Tumori " Fondazione

  • Universitair Ziekenhuis Gent, Ghent, Belgium

  • Istituto Nazionale Tumori, Milano, Italy

  • Clinica Universitaria de Navarra, Navarra, Spain

  • CHU Bordeaux, Bordeaux, France

  • Roche Pharma Research and Early

  • Roche Pharma Research and Early Development (pRED), Roche Innovation Center Basel, Basel, Switzerland

  • Rigshospitalet, Copenhagen, Denmark

  • Univer

  • Lille University Hospital,Lille,França

  • Universitair Ziekenhuis Gent, Ghent, Belgium

  • Seoul National University College of Medicine, Seoul, Korea

  • Department of Biomedical Sciences, Humanitas University and Department of Oncology and Hematology, IRCCS Humanitas Research Hospital,Milano,Italie

  • Hospital Universitario Marqués de Valdecilla. IDIVAL. Universidad de Cantabria., Cantabria, Spain

  • CHU nantes,Nantes ,Francia

  • Istituto Nazionale Tumori, Fondazione 'G. Pascale', IRCCS,Napoli,Itália

  • CHU Nantes, Nantes, France

  • Pathology,Peter MacCallum Cancer Centre,Melbourne,Australia;Sir Peter MacCallum Department of Oncology,The University of Melbourne,Parkville,Australia

  • Istituto Nazionale Tumori, Milano, Italy

  • CHU nantes,Nantes ,Francia

  • Lille University Hospital,Lille,França

  • University College London Hospitals NHS Foundation Trust,London,Vereinigtes Königreich

  • Roche Pharma Research and Early Development, Roche Innovation Center Munich,Penzberg,Deutschland

  • Peter MacCallum Cancer Center and Royal Melbourne Hospital, and Sir Peter MacCallum Department

  • Rigshospitalet, Copenhagen, Denmark

  • Rigshospitalet,Copenhagen,Дания

  • Universitair Ziekenhuis Gent, Ghent, Belgium

  • Roche Pharma Research and Early Development, Roche Innovation Center Munich, Munich, Germany

Locations

  • Switzerland

  • Germany

  • Denmark

  • Republic of South Korea

  • France

  • United States

  • Italy

  • Spain

  • Belgium

  • United Kingdom

  • Republic of South Korea

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Multiple Myeloma

Biomarkers

  • Nucleoside diphosphate kinase A

  • Cluster of differentiation 8A

  • Syndecan-1

Drug/Treatment

  • Uliprisnil acetate

Outcome

  • N/A

Study Design

  • Dose Escalation

Phase

  • I

Study Id's

  • NCT04557150

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved